# US 2013/0252944 A1 · Novel fused pyrazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0252944 A1
- Document ID: US20130252944A1
- Status: Published application
- Kind: A1
- Application number: 13/809,583
- Filed: 2011-07-11
- Published: 2013-09-26
- Earliest claimed: 2010-07-14
- Inventors: Christelle Bolea; Sylvain Celanire; Lam Tang; Philip Jones; Nigel J. Liverton; Richard Soll; Jingchao Dong; Zhiyu Lei; Fuqing Liu; Yanling Kong; Yi Ju; Haoyong Zhang; Jieping Wei; Qiaoxin Wei; Minxiang Zhang; Yunfu Luo
- Web page: https://patentgrep.com/patent/US20130252944A1

## CPC

- C07D 513/12: in which the condensed system contains three hetero rings
- A23L 27/2056: {having at least two different hetero atoms, at least one being a nitrogen atom}
- A23L 33/10: using additives (addition of substantially indigestible substances A23L33/21)
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/10: Dispersions; Emulsions
- A61K 9/2059: {Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin}
- A61K 31/429: condensed with heterocyclic ring systems
- A61K 31/433: Thidiazoles
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/06: Antimigraine agents
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07D 513/04: Ortho-condensed systems
- C07D 513/14: Ortho-condensed systems
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

The present invention relates to novel compounds of Formula (I), wherein M, A and Y are defined as in Formula (I); invention compounds are modulators of metabotropic glutamate receptors—subtype 4 (“mGluR4”) which are useful for the treatment or prevention of central nervous system disorders as well as other disorders modulated by mGluR4 receptors. The invention is also directed to pharmaceutical compositions and the use of such compounds in the manufacture of medicaments, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR4 is involved.

## Claims

### Claim 1

A compound having the Formula (I) wherein:
M is an optionally substituted heteroaryl;
A is NH or O;
Y is selected from the group of —CR1R2—, —CR1R2—CR3R4—, —CR1R2—CR3R4—CR5R6—, —CR1R2—CR3R4—CR5R6—CR7R8—, —CR1═CR2—, —CO—, —CO—CR1—R2—CR3R4—, —CR1R2—CR3R4—CO—, —CO—CR1R2—O—, —O—CR1R2—CO—, —NR9—CR1R2—CO—, —CO—NR9—, —NR9—CO—, —O—CR1R2—, —CR1R2—O—, —O—CR1R2—CR3R4—, —CR1R2—O—CR3R4—, —CR1R2—CR3R4—O—, —NR9—CR1R2—, —CR1R2—NR9—, —NR9—CR1R2—CR3R4—, —CR1R2—NR9—CR3R4—, —S—CR1R2—, —CR1R2—S—, —S—CR1R2—CR3R4—, —CR1R2—S—CR3R4—, —CR1R2—CR3R4—S—, —SO—CR1R2—, —CR1R2—SO—, —SO—CR1R2—CR3R4—, —CR1R2—SO—CR3R4—, —CR1R2—CR3R4—SO—, —SO2—CR1R2—, —CR1R2—SO2—, —SO2—CR1R2—CR3R4—, —CR1R2—SO2—CR3R4— and —CR1R2—CR3R4—SO2—;
R1, R2, R3, R4, R5, R6, R7 and R8 are each independently selected from the group of hydrogen, halogen, —CN, —CF3 or an optionally substituted radical selected from the group of —(C1-C6)alkyl, —(C1-C6)haloalkyl, —(C3-C7)cycloalkyl, aryl, heteroaryl, heterocycle, —(C1-C6)allylene-aryl, —(C1-C6)alkylene-heteroaryl, —(C1-C6)alkylene-heterocycle, —O—(C0-C6)alkyl, —N—((C0-C6)alkyl)2, —(C1-C6)alkyl-O—(C0-C6)alkyl, and —(C1-C6)alkyl-N—((C0-C6)alkyl)2;
Any two radicals of R (R1, R2, R3, R4, R5, R6, R7 or R8) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring; and
R9 is selected from the group of hydrogen or an optionally substituted radical selected from the group of —(C1-C6)alkyl, —(C1-C6)haloalkyl, —(C3-C7)cycloalkyl, —(C1-C6)alkylene-(C1-C6)haloalkyl, —(C1-C6)allylene-(C3-C7)halocycloalkyl, aryl, heteroaryl, heterocycle, —(C1-C6)alkylene-aryl, —(C1-C6)alkylene-heteroaryl, —(C1-C6)alkylene-heterocycle, —(C2-C6)alkyl-O—(C0-C6)alkyl, and —(C2-C6)alkyl-N—((C0-C6)alkyl)2.

### Claim 2 (depends on 1)

A compound according to claim 1 having the Formula (II):
provided that according to proviso (i) the compound is not:
N-(Pyridin-2-yl)-5,6-dihydro-4H-thiazolo[4,5-e]indazol-2-amine
N-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-thiazolo[4,5-e]indazol-2-amine
N-(6-Chloropyridin-2-yl)-5,6-dihydro-4H-thiazolo[4,5-e]indazol-2-amine
N-(6-Fluoropyridin-2-yl)-5,6-dihydro-4H-thiazolo[4,5-e]indazol-2-amine
4-Methyl-N-(pyridin-2-yl)-5,6-dihydro-4H-thiazolo[4,5-e]indazol-2-amine
Pyridin-2-yl-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
4-Ethyl-N-(pyridin-2-yl)-5,6-dihydro-4H-thiazolo[4,5-e]indazol-2-amine
N-(3-Fluoropyridin-2-yl)-5,6-dihydro-4H-thiazolo[4,5-e]indazol-2-amine
(6-Methyl-pyridin-2-yl)-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
(5-Fluoro-pyridin-2-yl)-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
(3-Fluoro-pyridin-2-yl)-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
(6-Methoxy-pyridin-2-yl)-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
N-(5-Fluoropyridin-2-yl)-5,6-dihydro-4H-thiazolo[4,5-e]indazol-2-amine
(6-Chloro-pyridin-2-yl)-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
N-(Pyrazin-2-yl)-5,6-dihydro-4H-thiazolo[4,5-e]indazol-2-amine
(6-Fluoro-pyridin-2-yl)-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
Pyrimidin-2-yl-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
N-(Pyrimidin-2-yl)-5,6-dihydro-4H-thiazolo[4,5-e]indazol-2-amine
(1-Methyl-1H-pyrazol-3-yl)-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
N-(1-Methyl-1H-pyrazol-3-yl)-5,6-dihydro-4H-thiazolo[4,5-e]indazol-2-amine
N-(4-Methylpyrimidin-2-yl)-5,6-dihydro-4H-thiazolo[4,5-e]indazol-2-amine
(4-Methyl-pyrimidin-2-yl)-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
4,4-Dimethyl-N-(pyridin-2-yl)-5,6-dihydro-4H-thiazolo[4,5-e]indazol-2-amine
4,4-Dimethyl-N-(pyrimidin-2-yl)-5,6-dihydro-4H-thiazolo[4,5-e]indazol-2-amine
4-Methyl-N-(pyrimidin-2-yl)-5,6-dihydro-4H-thiazolo[4,5-e]indazol-2-amine and
5,5-Dimethyl-N-(pyrimidin-2-yl)-5,6-dihydro-4H-thiazolo[4,5-e]indazol-2-amine;
provided that according to proviso (ii) the compound is not:
4,4-Dimethyl-N-(4-methylpyrimidin-2-yl)-5,6-dihydro-4H-[1,3]thiazolo[4,5-e]indazol-2-amine
N-(4-Methylpyrimidin-2-yl)-6H-[1,3]thiazolo[4,5-e]indazol-2-amine
N-(Pyrimidin-2-yl)-6H-[1,3]thiazolo[4,5-e]indazol-2-amine
N-(5-Fluoropyrimidin-2-yl)-4,4-dimethyl-5,6-dihydro-4H-[1,3]thiazolo[4,5-e]indazol-2-amine
N-(5-Fluoro-4-methylpyrimidin-2-yl)-4,4-dimethyl-5,6-dihydro-4H-[1,3]thiazolo[4,5-e]indazol-2-amine
5-Bromo-N-(pyrimidin-2-yl)-6H-[1,3]thiazolo[4,5-d]indazol-2-amine
5-Chloro-N-(pyrimidin-2-yl)-6H-[1,3]thiazolo[4,5-d]indazol-2-amine
5-Methyl-N-(4-methylpyrimidin-2-yl)-6H-[1,3]thiazolo[4,5-e]indazol-2-amine
5-Methyl-N-(pyrimidin-2-yl)-5,6-dihydro-4H-[1,3]thiazolo[4,5-e]indazol-2-amine
5-Methyl-N-(4-methylpyrimidin-2-yl)-5,6-dihydro-4H-[1,3]thiazolo[4,5-d]indazol-2-amine
N-(4-Methylpyrimidin-2-yl)-5′,6′-dihydrospiro[cyclopropane-1,4′-[1,3]thiazolo[4,5-d]indazol]-2′-amine
N-(Pyrimidin-2-yl)-5′,6′-dihydrospiro[cyclopropane-1,4′-[1,3]thiazolo[4,5-e]indazol]-2′-amine
N-(5-Fluoropyrimidin-2-yl)-5′,6′-dihydrospiro[cyclopropane-1,4′-[1,3]thiazolo[4,5-e]indazol]-2′-amine
N-(Pyrimidin-2-yl)-1,7-dihydropyrazolo[3′,4′:4,5]cyclopenta[1,2-d][1,3]thiazol-5-amine
N-(Pyrimidin-2-yl)-6,7-dihydro-4H-pyrazolo[4′,3′:5,6]oxepino[4,3-d][1,3]thiazol-2-amine
N-(5-Fluoropyrimidin-2-yl)-6,7-dihydro-4H-pyrazolo[4′,3′:5,6]oxepino[4,3-d][1,3]thiazol-2-amine
N-(4-Methylpyrimidin-2-yl)-6,7-dihydro-4H-pyrazolo[4′,3′:5,6]oxepino[4,3-d][1,3]thiazol-2-amine
(6-Methyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-(4-methyl-pyrimidin-2-yl)-amine
((R)-6-Methyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-(4-methyl-pyrimidin-2-yl)-amine
((S)-6-Methyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-(4-methyl-pyrimidin-2-yl)-amine
(6,7-Dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-(4-methoxy-pyrimidin-2-yl)-amine
(4-Isopropyl-pyrimidin-2-yl)-(6-methyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
(4-Ethyl-pyrimidin-2-yl)-(6-methyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
(4-Cyclopropyl-pyrimidin-2-yl)-(6-methyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
(N-(5-Fluoro-4-methylpyrimidin-2-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[4′,3′:5,6]oxepino[4,3-d][1,3]thiazol-2-amine)
(N-(5-Fluoropyrimidin-2-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[4′,3′:5,6]oxepino[4,3-d][1,3]thiazol-2-amine)
4-Methyl-N-(4-methylpyrimidin-2-yl)-6,7-dihydro-4H-pyrazolo[4′,3′:5,6]oxepino[4,3-d][1,3]thiazol-2-amine
4,6-Dimethyl-N-(4-methylpyrimidin-2-yl)-6,7-dihydro-4H-pyrazolo[4′,3′:5,6]oxepino-[4,3-d][1,3]thiazol-2-amine
N-(Pyrimidin-2-yl)-4,5,6,7-tetrahydropyrazolo[3,4-c][1,3]thiazolo[4,5-e]azepin-2-amine
5-Methyl-N-(4-methylpyrimidin-2-yl)-4,5,6,7-tetrahydropyrazolo[3,4-c][1,3]thiazolo[4,5-e]azepin-2-amine
N-(5-Fluoropyrimidin-2-yl)-4,5,6,7-tetrahydropyrazolo[3′,4′:6,7]cyclohepta[1,2-d][1,3]thiazol-2-amine
(5,5-Dimethyl-4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-(5-fluoro-pyrimidin-2-yl)-amine
6,6-Difluoro-N-(4-methylpyrimidin-2-yl)-4,5,6,7-tetrahydropyrazolo[3′,4′:6,7]cyclohepta[1,2-d][1,3]thiazol-2-amine
2-[(4-Methylpyrimidin-2-yl)amino]-4,7-dihydropyrazolo[3′,4′:6,7]cyclohepta[1,2-d][1,3]thiazol-6(5H)-one
5,5-Dimethyl-2-[(4-methylpyrimidin-2-yl)amino]-4,7-dihydropyrazolo[3′,4′:6,7]cyclohepta[1,2-d][1,3]thiazol-6(5H)-one
(6-Methyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-(5-methyl-[1,2,4]thiadiazol-3-yl)-amine and
(5-Fluoro-4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-(5-methyl-pyrimidin-2-yl)-amine;
provided that according to proviso (iii) the compound is not:
5,6-Dihydro-4H-3-thia-1,6,7-triaza-as-indacen-2-yl)-pyridin-4-yl-amine
(5,6-Dihydro-4H-3-thia-1,6,7-triaza-as-indacen-2-yl)-pyridin-3-yl-amine
(5,6-Dihydro-4H-3-thia-1,6,7-triaza-as-indacen-2-yl)-(5-methyl-pyridin-2-yl)-amine
(5,6-Dihydro-4H-3-thia-1,6,7-triaza-as-indacen-2-yl)-(4-methyl-pyridin-2-yl)-amine
(5,6-Dihydro-4H-3-thia-1,6,7-triaza-as-indacen-2-yl)-(4,6-dimethyl-pyridin-2-yl)-amine
Pyridin-3-yl-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
Pyrimidin-4-yl-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
Pyrazin-2-yl-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
(5-Methyl-1H-pyrazol-3-yl)-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
(1H-Pyrazol-3-yl)-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
(4,5,6,7-Tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-thiazol-2-yl-amine
(6-Methyl-pyridazin-3-yl)-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
(3-Methyl-pyridin-2-yl)-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
6-(4,5,6,7-Tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-ylamino)-pyridine-2-carbonitrile
(5-Methyl-pyridin-2-yl)-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
[6-(4,5,6,7-Tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-ylamino)-pyridin-2-yl]-methanol
6-(4,5,6,7-Tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-ylamino)-pyridine-2-carboxylic acid methyl ester
(4-Methoxy-pyrimidin-2-yl)-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
(6-Pyrrolidin-1-yl-pyridin-2-yl)-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
[4-(2-Methoxy-ethoxy)-pyrimidin-2-yl]-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
N,N-Dimethyl-N′-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-pyridine-2,6-diamine and
N-Ethyl-N′-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-pyridine-2,6-diamine.

### Claim 3 (depends on 2)

A compound according to claim 2 having the Formula (II) wherein:
Y is selected from the group of —CR1R2—, —CR1R2—CR3R4—, —CR1R2—CR3R4—CR5R6— and —CR1R2—CR3R4—CR5R6—CR7R8;
R1, R2, R3, R4, R5, R6, R7 and R8 are each independently selected from the group of hydrogen, halogen, —CN, —CF3 or an optionally substituted radical selected from the group of —(C1-C6)alkyl, —(C1-C6)haloalkyl, —(C3-C7)cycloalkyl, aryl, heteroaryl, heterocycle, —(C1-C6)allylene-aryl, —(C1-C6)alkylene-heteroaryl, —(C1-C6)alkylene-heterocycle, —O—(C0-C6)alkyl, —N—((C0-C6)alkyl)2, —(C1-C6)alkyl-O—(C0-C6)alkyl, and —(C1-C6)alkyl-N—((C0-C6)alkyl)2;
Any two radicals of R (R1, R2, R3, R4, R5, R6, R7 or R8) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring;
provided that according to proviso (i) the compound is not:
N-(Pyridin-2-yl)-5,6-dihydro-4H-thiazolo[4,5-e]indazol-2-amine
N-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-thiazolo[4,5-e]indazol-2-amine
N-(6-Chloropyridin-2-yl)-5,6-dihydro-4H-thiazolo[4,5-e]indazol-2-amine
N-(6-Fluoropyridin-2-yl)-5,6-dihydro-4H-thiazolo[4,5-e]indazol-2-amine
4-Methyl-N-(pyridin-2-yl)-5,6-dihydro-4H-thiazolo[4,5-e]indazol-2-amine
Pyridin-2-yl-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
4-Ethyl-N-(pyridin-2-yl)-5,6-dihydro-4H-thiazolo[4,5-e]indazol-2-amine
N-(3-Fluoropyridin-2-yl)-5,6-dihydro-4H-thiazolo[4,5-e]indazol-2-amine
(6-Methyl-pyridin-2-yl)-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
(5-Fluoro-pyridin-2-yl)-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
(3-Fluoro-pyridin-2-yl)-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
(6-Methoxy-pyridin-2-yl)-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
N-(5-Fluoropyridin-2-yl)-5,6-dihydro-4H-thiazolo[4,5-e]indazol-2-amine
(6-Chloro-pyridin-2-yl)-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
N-(Pyrazin-2-yl)-5,6-dihydro-4H-thiazolo[4,5-e]indazol-2-amine
(6-Fluoro-pyridin-2-yl)-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
Pyrimidin-2-yl-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
N-(Pyrimidin-2-yl)-5,6-dihydro-4H-thiazolo[4,5-e]indazol-2-amine
(1-Methyl-1H-pyrazol-3-yl)-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
N-(1-Methyl-1H-pyrazol-3-yl)-5,6-dihydro-4H-thiazolo[4,5-e]indazol-2-amine
N-(4-Methylpyrimidin-2-yl)-5,6-dihydro-4H-thiazolo[4,5-e]indazol-2-amine
(4-Methyl-pyrimidin-2-yl)-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
4,4-Dimethyl-N-(pyridin-2-yl)-5,6-dihydro-4H-thiazolo[4,5-e]indazol-2-amine
4,4-Dimethyl-N-(pyrimidin-2-yl)-5,6-dihydro-4H-thiazolo[4,5-e]indazol-2-amine
4-Methyl-N-(pyrimidin-2-yl)-5,6-dihydro-4H-thiazolo[4,5-e]indazol-2-amine and
5,5-Dimethyl-N-(pyrimidin-2-yl)-5,6-dihydro-4H-thiazolo[4,5-e]indazol-2-amine;
provided that according to proviso (iv) the compound is not:
4,4-Dimethyl-N-(4-methylpyrimidin-2-yl)-5,6-dihydro-4H-[1,3]thiazolo[4,5-e]indazol-2-amine
N-(5-Fluoropyrimidin-2-yl)-4,4-dimethyl-5,6-dihydro-4H-[1,3]thiazolo[4,5-e]indazol-2-amine
N-(5-Fluoro-4-methylpyrimidin-2-yl)-4,4-dimethyl-5,6-dihydro-4H-[1,3]thiazolo[4,5-e]indazol-2-amine
5-Methyl-N-(pyrimidin-2-yl)-5,6-dihydro-4H-[1,3]thiazolo[4,5-e]indazol-2-amine
5-Methyl-N-(4-methylpyrimidin-2-yl)-5,6-dihydro-4H-[1,3]thiazolo[4,5-e]indazol-2-amine
N-(4-Methylpyrimidin-2-yl)-5′,6′-dihydrospiro[cyclopropane-1,4′-[1,3]thiazolo[4,5-e]indazol]-2′-amine
N-(Pyrimidin-2-yl)-5′,6′-dihydrospiro[cyclopropane-1,4′-[1,3]thiazolo[4,5-e]indazol]-2′-amine
N-(5-Fluoropyrimidin-2-yl)-5′,6′-dihydrospiro[cyclopropane-1,4′-[1,3]thiazolo[4,5-e]indazol]-2′-amine
N-(Pyrimidin-2-yl)-1,7-dihydropyrazolo[3′,4′:4,5]cyclopenta[1,2-d][1,3]thiazol-5-amine
N-(5-Fluoropyrimidin-2-yl)-4,5,6,7-tetrahydropyrazolo[3′,4′:6,7]cyclohepta[1,2-d][1,3]thiazol-2-amine
(5,5-Dimethyl-4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-(5-fluoro-pyrimidin-2-yl)-amine
6,6-Difluoro-N-(4-methylpyrimidin-2-yl)-4,5,6,7-tetrahydropyrazolo[3′,4′:6,7]cyclohepta[1,2-d][1,3]thiazol-2-amine and
(5-Fluoro-4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-(5-methyl-pyrimidin-2-yl)-amine;
provided that according to proviso (iii) the compound is not:
5,6-Dihydro-4H-3-thia-1,6,7-triaza-as-indacen-2-yl)-pyridin-4-yl-amine
(5,6-Dihydro-4H-3-thia-1,6,7-triaza-as-indacen-2-yl)-pyridin-3-yl-amine
(5,6-Dihydro-4H-3-thia-1,6,7-triaza-as-indacen-2-yl)-(5-methyl-pyridin-2-yl)-amine
(5,6-Dihydro-4H-3-thia-1,6,7-triaza-as-indacen-2-yl)-(4-methyl-pyridin-2-yl)-amine
(5,6-Dihydro-4H-3-thia-1,6,7-triaza-as-indacen-2-yl)-(4,6-dimethyl-pyridin-2-yl)-amine
Pyridin-3-yl-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
Pyrimidin-4-yl-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
Pyrazin-2-yl-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
(5-Methyl-1H-pyrazol-3-yl)-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
(1H-Pyrazol-3-yl)-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
(4,5,6,7-Tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-thiazol-2-yl-amine
(6-Methyl-pyridazin-3-yl)-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
(3-Methyl-pyridin-2-yl)-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
6-(4,5,6,7-Tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-ylamino)-pyridine-2-carbonitrile
(5-Methyl-pyridin-2-yl)-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
[6-(4,5,6,7-Tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-ylamino)-pyridin-2-yl]-methanol
6-(4,5,6,7-Tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-ylamino)-pyridine-2-carboxylic acid methyl ester
(4-Methoxy-pyrimidin-2-yl)-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
(6-Pyrrolidin-1-yl-pyridin-2-yl)-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
[4-(2-Methoxy-ethoxy)-pyrimidin-2-yl]-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
N,N-Dimethyl-N′-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-pyridine-2,6-diamine and
N-Ethyl-N′-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-pyridine-2,6-diamine.

### Claim 4 (depends on 3)

A compound according to claim 3 having the Formula (H) wherein:
Y is selected from the group of —CR1R2—, —CR1R2—CR3R4—, —CR1R2—CR3R4—CR5R6— and —CR1R2—CR3R4—CR5R6—CR7R8;
M is an optionnally substituted pyrimidinyl;
R1, R2, R3 or R4 are each independently selected from the group of hydrogen, fluoro, CF3, OMe, methyl and propyl;
provided that according to proviso (v) the compound is not:
Pyrimidin-2-yl-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
N-(Pyrimidin-2-yl)-5,6-dihydro-4H-thiazolo[4,5-e]indazol-2-amine
N-(4-Methylpyrimidin-2-yl)-5,6-dihydro-4H-thiazolo[4,5-e]indazol-2-amine
(4-Methyl-pyrimidin-2-yl)-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
4,4-Dimethyl-N-(pyrimidin-2-yl)-5,6-dihydro-4H-thiazolo[4,5-e]indazol-2-amine
4-Methyl-N-(pyrimidin-2-yl)-5,6-dihydro-4H-thiazolo[4,5-e]indazol-2-amine and
5,5-Dimethyl-N-(pyrimidin-2-yl)-5,6-dihydro-4H-thiazolo[4,5-e]indazol-2-amine;
provided that according to proviso (vi) the compound is not:
4,4-Dimethyl-N-(4-methylpyrimidin-2-yl)-5,6-dihydro-4H-[1,3]thiazolo[4,5-e]indazol-2-amine
N-(5-Fluoropyrimidin-2-yl)-4,4-dimethyl-5,6-dihydro-4H-[1,3]thiazolo[4,5-e]indazol-2-amine
N-(5-Fluoro-4-methylpyrimidin-2-yl)-4,4-dimethyl-5,6-dihydro-4H-[1,3]thiazolo[4,5-e]indazol-2-amine
5-Methyl-N-(pyrimidin-2-yl)-5,6-dihydro-4H-[1,3]thiazolo[4,5-e]indazol-2-amine
5-Methyl-N-(4-methylpyrimidin-2-yl)-5,6-dihydro-4H-[1,3]thiazolo[4,5-e]indazol-2-amine
N-(Pyrimidin-2-yl)-1,7-dihydropyrazolo[3′,4′:4,5]cyclopenta[1,2-d][1,3]thiazol-5-amine
N-(5-Fluoropyrimidin-2-yl)-4,5,6,7-tetrahydropyrazolo[3′,4′:6,7]cyclohepta[1,2-d][1,3]thiazol-2-amine
(5,5-Dimethyl-4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-(5-fluoro-pyrimidin-2-yl)-amine
6,6-Difluoro-N-(4-methylpyrimidin-2-yl)-4,5,6,7-tetrahydropyrazolo[3′,4′:6,7]cyclohepta[1,2-d][1,3]thiazol-2-amine and
(5-Fluoro-4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-(5-methyl-pyrimidin-2-yl)-amine;
provided that according to proviso (vii) the compound is not:
Pyrimidin-4-yl-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
(4-Methoxy-pyrimidin-2-yl)-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine and
[4-(2-Methoxy-ethoxy)-pyrimidin-2-yl]-(4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine.

### Claim 5 (depends on 2)

A compound according to claim 2 having the Formula (II) wherein:
Y is selected from the group of —O—CR1R2—, —O—CR1R2—CR3R4—, —NR9—CR1R2— and —NR9—CR1R2—CR3R4—;
R1, R2, R3 or R4 are each independently selected from the group of hydrogen, halogen, —CN, —CF3 or an optionally substituted radical selected from the group of —(C1-C6)alkyl, —(C1-C6)haloalkyl, —(C3-C7)cycloalkyl, aryl, heteroaryl, heterocycle, —(C1-C6)alkylene-aryl, —(C1-C6)alkylene-heteroaryl, —(C1-C6)alkylene-heterocycle, —O—(C0-C6)alkyl, —N—((C0-C6)alkyl)2, —(C1-C6)alkyl-O—(C0-C6)allyl, and —(C1-C6)alkyl-N—((C0-C6)alkyl)2;
Any two radicals of R (R1, R2, R3 or R4) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring; and
R9 is selected from the group of hydrogen or an optionally substituted radical selected from the group of —(C1-C6)alkyl, —(C1-C6)haloalkyl, —(C3-C7)cycloalkyl, —(C1-C6)alkylene-(C1-C6)haloalkyl, —(C1-C6)alkylene-(C3-C7)halocycloalkyl, aryl, heteroaryl, heterocycle, —(C1-C6)alkylene-aryl, —(C1-C6)alkylene-heteroaryl, —(C1-C6)alkylene-heterocycle, —(C1-C6)alkylene-(C3-C7)cycloalkyl, —(C2-C6)alkyl-O—(C0-C6)alkyl, and —(C2-C6)alkyl-N—((C0-C6)alkyl)2.

### Claim 6 (depends on 2)

A compound according to claim 2 having the Formula (II) wherein:
Y is selected from the group of —O—CR1R2—, —O—CR1R2—CR3R4—, —NR9—CR1R2— and NR9—CR1R2—CR3R4—;
R1, R2, R3 or R4 are each independently selected from the group of hydrogen, halogen, —CN, —CF3 or an optionally substituted radical selected from the group of —(C1-C6)allyl, —(C1-C6)haloalkyl, —(C3-C7)cycloalkyl, aryl, heteroaryl, heterocycle, —(C1-C6)alkylene-aryl, —(C1-C6)allylene-heteroaryl, —(C1-C6)alkylene-heterocycle, —O—(C0-C6)alkyl, —N—((C0-C6)alkyl)2, —(C1-C6)alkyl-O—(C0-C6)allyl, and —(C1-C6)alkyl-N—((C0-C6)alkyl)2;
Any two radicals of R (R1, R2, R3 or R4) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring; and
R9 is selected from the group of hydrogen or an optionally substituted radical selected from the group of —(C1-C6)alkyl, —(C1-C6)haloalkyl, —(C3-C7)cycloalkyl, —(C1-C6)alkylene-(C1-C6)haloalkyl, —(C1-C6)allylene-(C3-C7)halocycloalkyl, aryl, heteroaryl, heterocycle, —(C1-C6)alkylene-aryl, —(C1-C6)alkylene-heteroaryl, —(C1-C6)allylene-heterocycle, —(C2-C6)alkyl-O—(C0-C6)alkyl, and —(C2-C6)alkyl-N—((C0-C6)alkyl)2.

### Claim 7 (depends on 2)

A compound according to claim 2 having the Formula (II) wherein:
Y is selected from the group of —CR1R2—O—CR3R4— and —CR1R2—NR9—CR3R4—;
R1, R2, R3 or R4 are each independently selected from the group of hydrogen, —CN, —CF3 or an optionally substituted radical selected from the group of —(C1-C6)alkyl, —(C1-C6)haloalicyl, —(C3-C7)cycloalkyl, aryl, heteroaryl, heterocycle, —(C1-C6)alkylene-aryl, —(C1-C6)alkylene-heteroaryl, —(C1-C6)alkylene-heterocycle, —(C1-C6)alkyl-O—(C0-C6)alkyl, and —(C1-C6)alkyl-N—((C0-C6)alkyl)2;
Any two radicals of R (R1, R2, R3 or R4) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring; and
R9 is selected from the group of hydrogen or an optionally substituted radical selected from the group of —(C1-C6)alkyl, —(C1-C6)haloalkyl, —(C3-C7)cycloalkyl, —(C1-C6)alkylene-(C1-C6)haloalkyl, —(C1-C6)allylene-(C3-C7)halocycloalkyl, aryl, heteroaryl, heterocycle, —(C1-C6)alkylene-aryl, —(C1-C6)alkylene-heteroaryl, —(C1-C6)alkylene-hetero cycle, —(C1-C6)alkylene-(C3-C7)cycloalkyl, —(C2-C6)alkyl-O—(C0-C6)alkyl, and —(C2-C6)alkyl-N—((C0-C6)alkyl)2;
provided that according to proviso (viii) the compound is not:
N-(Pyrimidin-2-yl)-6,7-dihydro-4H-pyrazolo[4′,3′:5,6]oxepino[4,3-d][1,3]thiazol-2-amine
N-(5-Fluoropyrimidin-2-yl)-6,7-dihydro-4H-pyrazolo[4′,3′:5,6]oxepino[4,3-d][1,3]thiazol-2-amine
N-(4-Methylpyrimidin-2-yl)-6,7-dihydro-4H-pyrazolo[4′,3′:5,6]oxepino[4,3-c][1,3]thiazol-2-amine
(6-Methyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-(4-methyl-pyrimidin-2-yl)-amine
((R)-6-Methyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-(4-methyl-pyrimidin-2-yl)-amine
((S)-6-Methyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-(4-methyl-pyrimidin-2-yl)-amine
(6,7-Dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-(4-methoxy-pyrimidin-2-yl)-amine
(4-Isopropyl-pyrimidin-2-yl)-(6-methyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
(4-Ethyl-pyrimidin-2-yl)-(6-methyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
(4-Cyclopropyl-pyrimidin-2-yl)-(6-methyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
(N-(5-Fluoro-4-methylpyrimidin-2-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[4′,3′:5,6]oxepino[4,3-d][1,3]thiazol-2-amine)
(N-(5-Fluoropyrimidin-2-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[4′,3′:5,6]oxepino[4,3-d][1,3]thiazol-2-amine)
4-Methyl-N-(4-methylpyrimidin-2-yl)-6,7-dihydro-4H-pyrazolo[4′,3′:5,6]oxepino[4,3-d][1,3]thiazol-2-amine
4,6-Dimethyl-N-(4-methylpyrimidin-2-yl)-6,7-dihydro-4H-pyrazolo[4′,3′:5,6]oxepino-[4,3-d][1,3]thiazol-2-amine
N-(Pyrimidin-2-yl)-4,5,6,7-tetrahydropyrazolo[3,4-c][1,3]thiazolo[4,5-e]azepin-2-amine
5-Methyl-N-(4-methylpyrimidin-2-yl)-4,5,6,7-tetrahydropyrazolo[3,4-c][1,3]thiazolo[4,5-e]azepin-2-amine and
(6-Methyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-(5-methyl-[1,2,4]thiadiazol-3-yl)-amine.

### Claim 8 (depends on 2)

A compound according to claim 2 having the Formula (II) wherein:
Y is selected from the group of —CR1R2—O—CR3R4— and —CR1R2—NR9—CR3R4—;
R1, R2, R3 or R4 are each independently selected from the group of hydrogen, —CN, —CF3 or an optionally substituted radical selected from the group of —(C1-C6)alkyl, —(C1-C6)haloalkyl, —(C3-C7)cycloalkyl, aryl, heteroaryl, heterocycle, —(C1-C6)alkylene-aryl, —(C1-C6)alkylene-heteroaryl, —(C1-C6)alkylene-heterocycle, —(C1-C6)alkyl-O—(C0-C6)alkyl, and —(C1-C6)alkyl-N—((C0-C6)alkyl)2;
Any two radicals of R (R1, R2, R3 or R4) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring; and
R9 is selected from the group of hydrogen or an optionally substituted radical selected from the group of —(C1-C6)alkyl, —(C1-C6)haloalkyl, —(C3-C7)cycloalkyl, —(C1-C6)alkylene-(C1-C6)haloalkyl, —(C1-C6)alkylene-(C3-C7)halocycloalkyl, aryl, heteroaryl, heterocycle, —(C1-C6)alkylene-aryl, —(C1-C6)alkylene-heteroaryl, —(C1-C6)alkylene-heterocycle, —(C2-C6)alkyl-O—(C0-C6)alkyl, and —(C2-C6)alkyl-N—((C0-C6)alkyl)2;
provided that according to proviso (viii) the compound is not:
N-(Pyrimidin-2-yl)-6,7-dihydro-4H-pyrazolo[4′,3′:5,6]oxepino[4,3-d][1,3]thiazol-2-amine
N-(5-Fluoropyrimidin-2-yl)-6,7-dihydro-4H-pyrazolo[4′,3′:5,6]oxepino[4,3-d][1,3]thiazol-2-amine
N-(4-Methylpyrimidin-2-yl)-6,7-dihydro-4H-pyrazolo[4′,3′:5,6]oxepino[4,3-d][1,3]thiazol-2-amine
(6-Methyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-(4-methyl-pyrimidin-2-yl)-amine
((R)-6-Methyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-(4-methyl-pyrimidin-2-yl)-amine
((S)-6-Methyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-(4-methyl-pyrimidin-2-yl)-amine
(6,7-Dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-(4-methoxy-pyrimidin-2-yl)-amine
(4-Isopropyl-pyrimidin-2-yl)-(6-methyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
(4-Ethyl-pyrimidin-2-yl)-(6-methyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
(4-Cyclopropyl-pyrimidin-2-yl)-(6-methyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
(N-(5-Fluoro-4-methylpyrimidin-2-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[4′,3′:5,6]oxepino[4,3-d][1,3]thiazol-2-amine)
(N-(5-Fluoropyrimidin-2-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[4′,3′:5,6]oxepino[4,3-d][1,3]thiazol-2-amine)
4-Methyl-N-(4-methylpyrimidin-2-yl)-6,7-dihydro-4H-pyrazolo[4′,3′:5,6]oxepino[4,3-d][1,3]thiazol-2-amine
4,6-Dimethyl-N-(4-methylpyrimidin-2-yl)-6,7-dihydro-4H-pyrazolo[4′,3′:5,6]oxepino-[4,3-d][1,3]thiazol-2-amine
N-(Pyrimidin-2-yl)-4,5,6,7-tetrahydropyrazolo[3,4-c][1,3]thiazolo[4,5-e]azepin-2-amine
5-Methyl-N-(4-methylpyrimidin-2-yl)-4,5,6,7-tetrahydropyrazolo[3,4-c][1,3]thiazolo[4,5-e]azepin-2-amine and
(6-Methyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-(5-methyl-[1,2,4]thiadiazol-3-yl)-amine.

### Claim 9 (depends on 8)

A compound according to claim 8 having the Formula (III) wherein:
M is an optionally substituted pyridinyl, pyrimidinyl, thiadiazolyl, triazinyl, thiazolyl and oxadiazolyl;
R1, R2, R3 or R4 are each independently selected from the group of hydrogen or an optionally substituted radical selected from the group of —(C1-C6)alkyl, —(C1-C6)haloalkyl, —(C3-C7)cycloalkyl, aryl, heteroaryl, heterocycle, —(C1-C6)alkylene-aryl, —(C1-C6)alkylene-heteroaryl, —(C1-C6)alkylene-heterocycle, —(C1-C6)alkyl-O—(C0-C6)alkyl, and —(C1-C6)alkyl-N—((C0-C6)alkyl)2; and
Any two radicals of R (R1, R2, R3 or R4) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring;
provided that according to proviso (ix) the compound is not:
N-(Pyrimidin-2-yl)-6,7-dihydro-4H-pyrazolo[4′,3′:5,6]oxepino[4,3-d][1,3]thiazol-2-amine
N-(5-Fluoropyrimidin-2-yl)-6,7-dihydro-4H-pyrazolo[4′,3′:5,6]oxepino[4,3-d][1,3]thiazol-2-amine
N-(4-Methylpyrimidin-2-yl)-6,7-dihydro-4H-pyrazolo[4′,3′:5,6]oxepino[4,3-d][1,3]thiazol-2-amine
(6-Methyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-(4-methyl-pyrimidin-2-yl)-amine
((R)-6-Methyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-(4-methyl-pyrimidin-2-yl)-amine
((S)-6-Methyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-(4-methyl-pyrimidin-2-yl)-amine
(6,7-Dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-(4-methoxy-pyrimidin-2-yl)-amine
(4-Isopropyl-pyrimidin-2-yl)-(6-methyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
(4-Ethyl-pyrimidin-2-yl)-(6-methyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
(4-Cyclopropyl-pyrimidin-2-yl)-(6-methyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
(N-(5-Fluoro-4-methylpyrimidin-2-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[4′,3′:5,6]oxepino[4,3-d][1,3]thiazol-2-amine)
(N-(5-Fluoropyrimidin-2-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[4′,3′:5,6]oxepino[4,3-d][1,3]thiazol-2-amine)
4-Methyl-N-(4-methylpyrimidin-2-yl)-6,7-dihydro-4H-pyrazolo[4′,3′:5,6]oxepino[4,3-d][1,3]thiazol-2-amine
4,6-Dimethyl-N-(4-methylpyrimidin-2-yl)-6,7-dihydro-4H-pyrazolo[4′,3′:5,6]oxepino-[4,3-d][1,3]thiazol-2-amine and
(6-Methyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-(5-methyl-[1,2,4]thiadiazol-3-yl)-amine.

### Claim 10 (depends on 9)

A compound according to claim 9 having the Formula (III) wherein:
M is an optionally substituted pyridinyl, pyrimidinyl and thiadiazolyl;
R1, R2, R3 or R4 are each independently selected from the group of hydrogen, CF3, methyl, ethyl, isopropyl, and an optionally substituted pyridinyl;
provided that according to proviso (ix) the compound is not:
N-(Pyrimidin-2-yl)-6,7-dihydro-4H-pyrazolo[4′,3′:5,6]oxepino[4,3-d][1,3]thiazol-2-amine
N-(5-Fluoropyrimidin-2-yl)-6,7-dihydro-4H-pyrazolo[4′,3′:5,6]oxepino[4,3-d][1,3]thiazol-2-amine
N-(4-Methylpyrimidin-2-yl)-6,7-dihydro-4H-pyrazolo[4′,3′:5,6]oxepino[4,3-d][1,3]thiazol-2-amine
(6-Methyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-(4-methyl-pyrimidin-2-yl)-amine
((R)-6-Methyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-(4-methyl-pyrimidin-2-yl)-amine
((S)-6-Methyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-(4-methyl-pyrimidin-2-yl)-amine
(6,7-Dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-(4-methoxy-pyrimidin-2-yl)-amine
(4-Isopropyl-pyrimidin-2-yl)-(6-methyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
(4-Ethyl-pyrimidin-2-yl)-(6-methyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
(4-Cyclopropyl-pyrimidin-2-yl)-(6-methyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
(N-(5-Fluoro-4-methylpyrimidin-2-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[4′,3′:5,6]oxepino[4,3-d][1,3]thiazol-2-amine)
(N-(5-Fluoropyrimidin-2-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[4′,3′:5,6]oxepino[4,3-d][1,3]thiazol-2-amine)
4-Methyl-N-(4-methylpyrimidin-2-yl)-6,7-dihydro-4H-pyrazolo[4′,3′:5,6]oxepino[4,3-d][1,3]thiazol-2-amine
4,6-Dimethyl-N-(4-methylpyrimidin-2-yl)-6,7-dihydro-4H-pyrazolo[4′,3′:5,6]oxepino-[4,3-d][1,3]thiazol-2-amine and
(6-Methyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-(5-methyl-[1,2,4]thiadiazol-3-yl)-amine.

### Claim 11 (depends on 2)

A compound according to claim 2 having the Formula (II) wherein:
Y is selected from the group of —CR1R2—O—, —CR1R2—CR3R4—O— and —CR1R2—NR9—;
R1, R2, R3 or R4 are each independently selected from the group of hydrogen, halogen, —CN, —CF3 or an optionally substituted radical selected from the group of —(C1-C6)alkyl, —(C1-C6)haloalkyl, —(C3-C7)cycloalkyl, aryl, heteroaryl, heterocycle, —(C1-C6)alkylene-aryl, —(C1-C6)alkylene-heteroaryl, —(C1-C6)alkylene-heterocycle, —O—(C0-C6)alkyl, —N—((C0-C6)alkyl)2, —(C1-C6)alkyl-O—(C0-C6)allyl, and —(C1-C6)alkyl-N—((C0-C6)alkyl)2;
Any two radicals of R(R1, R2, R3 or R4) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring; and
R9 is selected from the group of hydrogen or an optionally substituted radical selected from the group of —(C1-C6)alkyl, —(C1-C6)haloalkyl, —(C3-C7)cycloalkyl, (C1-C6)alkylene-(C1-C6)haloalkyl, —(C1-C6)allylene-(C3-C7)halocycloalkyl, aryl, heteroaryl, heterocycle, —(C1-C6)allylene-aryl, —(C1-C6)alkylene-heteroaryl, —(C1-C6)alkylene-heterocycle, —(C1-C6)alkylene-(C3-C7)cycloalkyl, —(C2-C6)alkyl-O—(C0-C6)alkyl, and —(C2-C6)alkyl-N—((C0-C6)alkyl)2.

### Claim 12 (depends on 2)

A compound according to claim 2 having the Formula (II) wherein:
Y is selected from the group of —CR1R2—O—, —CR1R2—CR3R4—O— and —CR1R2—NR9—;
R1, R2, R3 or R4 are each independently selected from the group of hydrogen, halogen, —CN, —CF3 or an optionally substituted radical selected from the group of —(C1-C6)alkyl, —(C1-C6)haloalkyl, —(C3-C7)cycloalkyl, aryl, heteroaryl, heterocycle, —(C1-C6)alkylene-aryl, —(C1-C6)alkylene-heteroaryl, —(C1-C6)allylene-heterocycle, —O—(C0-C6)alkyl, —N—((C0-C6)alkyl)2, —(C1-C6)alkyl-O—(C0-C6)allyl, and —(C1-C6)alkyl-N—((C0-C6)alkyl)2;
Any two radicals of R (R1, R2, R3 or R4) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring; and
R9 is selected from the group of hydrogen or an optionally substituted radical selected from the group of —(C1-C6)alkyl, —(C1-C6)haloalkyl, —(C3-C7)cycloalkyl, —(C1-C6)alkylene-(C1-C6)haloalkyl, —(C1-C6)alkylene-(C3-C7)halocycloalkyl, aryl, heteroaryl, heterocycle, —(C1-C6)alkylene-aryl, —(C1-C6)allylene-heteroaryl, —(C1-C6)alkylene-heterocycle, —(C2-C6)alkyl-O—(C0-C6)alkyl, and —(C2-C6)alkyl-N—((C0-C6)alkyl)2.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

A compound according to claims 1 to 12, which can exist as optical isomers, wherein said compound is either the racemic mixture or one or both of the individual optical isomers.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A compound according to claims 1 to 13, wherein said compound is selected from:
(4-Methyl-6H-3-thia-1,6,7-triaza-as-indacen-2-yl)-pyridin-2-yl-amine
(4-Methyl-pyrimidin-2-yl)-(4,4,6-trimethyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
2-(4-Methyl-pyrimidin-2-ylamino)-4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-6-ol
(4,4-Dimethyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-(4-methyl-pyrimidin-2-yl)-amine
(4-Methyl-pyrimidin-2-yl)-(5-propyl-5,6-dihydro-4H-3-thia-1,6,7-triaza-as-indacen-2-yl)-amine
Dimethyl-carbamic acid 2-(4-methyl-pyrimidin-2-ylamino)-4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-5-yl ester
(4-Methyl-pyrimidin-2-yl)-(5,6,7,8-tetrahydro-4H-3-thia-1,8,9-triaza-dicyclopenta[a,c]cycloocten-2-yl)-amine
(6-Ethyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-(4-methyl-pyrimidin-2-yl)-amine
(6,6-Difluoro-5,5-dimethyl-4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-(4-methyl-pyrimidin-2-yl)-amine
(6,6-Dimethyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-(4-methyl-pyrimidin-2-yl)-amine
(4-Methyl-pyrimidin-2-yl)-(5-methyl-4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
(4-Methyl-pyrimidin-2-yl)-(6-methyl-4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
(4-Methyl-pyrimidin-2-yl)-(6-trifluoromethyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
(4-Methoxy-pyrimidin-2-yl)-(6-methyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
(5-Methoxy-4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-(4-methyl-pyrimidin-2-yl)-amine
(6-Isopropyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-(4-methyl-pyrimidin-2-yl)-amine
(4,7-Dihydro-5H-6-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-(4-methyl-pyrimidin-2-yl)-amine
(5,5-Difluoro-4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-(4-methyl-pyrimidin-2-yl)-amine
(6-Ethyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-(5-fluoro-pyrimidin-2-yl)-amine
(6-Ethyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-(5-methyl-[1,2,4]thiadiazol-3-yl)-amine
(6-Ethyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-(5-fluoro-4-methyl-pyrimidin-2-yl)-amine
(6-Ethyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-(4-methoxy-pyrimidin-2-yl)-amine
(6-Fluoro-pyridin-2-yl)-(6-methyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
(6-Methoxy-4,5,6,8-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-(4-methyl-pyrimidin-2-yl)-amine
(6-Isopropyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-(5-methyl-[1,2,4]thiadiazol-3-yl)-amine
(6-Fluoro-pyridin-2-yl)-(6-isopropyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
(4-Methyl-pyrimidin-2-yl)-(6-trifluoromethyl-4,5,6,7-tetrahydro-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
(5-Fluoro-pyrimidin-2-yl)-(6-isopropyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
(5-Fluoro-4-methyl-pyrimidin-2-yl)-(6-isopropyl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
2-(5-Fluoro-4-methyl-pyrimidin-2-ylamino)-6,7-dihydro-5H-3-thia-1,7,8-triaza-cyclopenta[e]azulen-4-one
(4-Methyl-pyrimidin-2-yl)-(6-pyridin-2-yl-6,7-dihydro-4H-5-oxa-3-thia-1,7,8-triaza-cyclopenta[e]azulen-2-yl)-amine
and a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof and an N-oxide form thereof.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claims 1 to 14 and a pharmaceutically acceptable carrier and/or excipient.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

A method of treating or preventing a condition in a mammal, including a human, the treatment or prevention of which is affected or facilitated by the neuromodulatory effect of mGluR4 allosteric modulators, comprising administering to a mammal in need of such treatment or prevention, an effective amount of a compound/composition according to claims 1 to 15.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

A method of treating or preventing a condition in a mammal, including a human, the treatment or prevention of which is affected or facilitated by the neuromodulatory effect of mGluR4 positive allosteric modulators, comprising administering to a mammal in need of such treatment or prevention, an effective amount of a compound/composition according to claims 1 to 15.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

A method useful for treating or preventing central nervous system disorders selected from the group consisting of: addiction, tolerance or dependence; affective disorders, such as depression and anxiety; psychiatric disease such as psychotic disorders, attention-deficit/hyperactivity disorder and bipolar disorder; Parkinson's disease, memory impairment, Alzheimer's disease, dementia, delirium tremens, other forms of neurodegeneration, neurotoxicity, and ischemia, comprising administering to a mammalian patient in need of such treatment or prevention, an effective amount of a compound/composition according to claims 1 to 15.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

A method useful for treating or preventing central nervous system disorders selected from the group consisting of Parkinson's disease and movement disorders such as bradykinesia, rigidity, dystonia, drug-induced parkinsonism, dyskinesia, tardive dyskinesia, L-DOPA-induced dyskinesia, dopamine agonist-induced dyskinesia, hyperkinetic movement disorders, Gilles de la Tourette syndrome, resting tremor, action tremor, akinesia, akinetic-rigid syndrome, akathisia, athetosis, asterixis, tics, postural instability, postencephalitic parkinsonism, muscle rigidity, chorea and choreaform movements, spasticity, myoclonus, hemiballismus, progressive supranuclear palsy, restless legs syndrome, and periodic limb movement disorder, comprising administering to a mammalian patient in need of such treatment or prevention, an effective amount of a compound/composition according to claims 1 to 15.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 19)

A method of claim 19 comprising administering to a mammalian patient in need of such treatment or prevention, an effective amount of a compound/composition according to claims 1 to 15 in combination with an agent selected from the group consisting of: levodopa, levodopa with a selective extracerebral decarboxylase inhibitor, carbidopa, entacapone, a COMT inhibitor, a dopamine agonist, an anticholinergic, a cholinergic agonist, a butyrophenone neuroleptic agent, a diphenylbutylpiperidine neuroleptic agent, a heterocyclic dibenzazepine neuroleptic agent, an indolone neuroleptic agent, a phenothiazine neuroleptic agent, a thioxanthene neuroleptic agent, an NMDA receptor antagonist, an MAO-B inhibitor, an mGluR5 antagonist or an A2A antagonist.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

A method useful for treating or preventing central nervous system disorders selected from the group consisting of: cognitive disorders such as delirium, substance-induced persisting delirium, dementia, dementia due to HIV disease, dementia due to Huntington's disease, dementia due to Parkinson's disease, Parkinsonian-ALS demential complex, dementia of the Alzheimer's type, substance-induced persisting dementia, and mild cognitive impairment, comprising administering to a mammalian patient in need of such treatment or prevention, an effective amount of a compound/composition according to claims 1 to 15.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

A method useful for treating affective disorders selected from the group consisting of: anxiety, agoraphobia, generalized anxiety disorder (GAD), obsessive-compulsive disorder (OCD), panic disorder, posttraumatic stress disorder (PTSD), social phobia, other phobias, substance-induced anxiety disorder, and acute stress disorder, comprising administering to a mammalian patient in need of such treatment, an effective amount of a compound/composition according to claims 1 to 15.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

A method useful for treating or preventing central nervous system disorders selected from the group consisting of: mood disorders, Bipolar Disorders (I & II), Cyclothymic Disorder, Depression, Dysthymic Disorder, Major Depressive Disorder, and Substance-Induced Mood Disorder, comprising administering to a mammalian patient in need of such treatment or prevention, an effective amount of a compound/composition according to claims 1 to 15.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

A method useful for treating or preventing neurological disorders selected from the group consisting of: neurodegeneration, neurotoxicity or ischemia such as stroke, spinal cord injury, cerebral hypoxia, intracranial hematoma, Parkinson's disease, memory impairment, Alzheimer's disease, dementia, and delirium tremens, comprising administering to a mammalian patient in need of such treatment or prevention, an effective amount of a compound/composition according to claims 1 to 15.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

A method useful for treating or preventing inflammatory central nervous system disorders selected from the group consisting of: multiple sclerosis forms such as benign multiple sclerosis, relapsing-remitting multiple sclerosis, secondary progressive multiple sclerosis, primary progressive multiple sclerosis, and progressive-relapsing multiple sclerosis, comprising administering to a mammalian patient in need of such treatment or prevention, an effective amount of a compound/composition according to claims 1 to 15.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

A method useful for treating or preventing migraine, comprising administering to a mammalian patient in need of such treatment or prevention, an effective amount of a compound/composition according to claims 1 to 15.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

A method useful for treating or preventing epilepsy and tremor, temporal lobe epilepsy, epilepsy secondary to another disease or injury such as chronic encephalitis, traumatic brain injury, stroke or ischemia, comprising administering to a mammalian patient in need of such treatment or prevention, an effective amount of a compound/composition according to claims 1 to 15.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

A method useful for treating or preventing inflammation and/or neurodegeneration resulting from traumatic brain injury, stroke, ischemia, spinal cord injury, cerebral hypoxia or intracranial hematoma, comprising administering to a mammalian patient in need of such treatment or prevention, an effective amount of a compound/composition according to claims 1 to 15.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

A method useful for treating or preventing sensory, motor or cognitive symptoms resulting from traumatic brain injury, stroke, ischemia, spinal cord injury, cerebral hypoxia or intracranial hematoma, comprising administering to a mammalian patient in need of such treatment or prevention, an effective amount of a compound/composition according to claims 1 to 15.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

A method useful for treating medulloblastomas, comprising administering to a mammalian patient in need of such treatment, an effective amount of a compound/composition according to claims 1 to 15.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

A method useful for treating or preventing inflammatory or neuropathic pain, comprising administering to a mammalian patient in need of such treatment or prevention, an effective amount of a compound/composition according to claims 1 to 15.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

A method useful for treating, preventing, ameliorating, controlling or reducing the risk of various metabolic disorders associated with glutamate dysfunction, comprising administering to a mammalian patient in need of such treatment, prevention, amelioration or control of the risk, an effective amount of a compound/composition according to claims 1 to 15.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

A method useful for treating or preventing type 2 diabetes, comprising administering to a mammalian patient in need of such treatment or prevention, an effective amount of a compound/composition according to claims 1 to 15.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

A method useful for treating or preventing diseases or disorders of the retina, retinal degeneration or macular degeneration, comprising administering to a mammalian patient in need of such treatment or prevention, an effective amount of a compound/composition according to claims 1 to 15.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

A method useful for treating or preventing diseases or disorders of the gastrointestinal tract including gastro-esophageal reflux disease (GERD), lower esophageal sphincter diseases or disorders, diseases of gastrointestinal motility, colitis, Crohn's disease or irritable bowel syndrome (IBS), comprising administering to a mammalian patient in need of such treatment or prevention, an effective amount of a compound/composition according to claims 1 to 15.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

Use of a compound according to claims 1 to 14 in the manufacture of a medicament for a use as defined in any of claims 16 to 35.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

Use of a compound according to claims 1 to 14 to prepare a tracer for imaging a metabotropic glutamate receptor.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

Use of a compound according to claims 1 to 14 as a taste agent, flavour agent, flavour enhancing agent or a food or beverage additive.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 23, 24, 25, 26, 27, 28, 29, 31, 33, 34, 35)

A compound according to claims 1 to 14 or a composition according to claim 15 for a use in a treatment or prevention as defined in any of claims 16 to 21, 23 to 29, 31 and 33 to 35.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 32)

A compound according to claims 1 to 14 or a composition according to claim 15 for a use as defined in claim 32.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 22, 30)

A compound according to claims 1 to 14 or a composition according to claim 15 for a use in a treatment as defined in any of claims 22 and 30.
